GLP-Compliant Study Design for IND-Enabling Toxicology Testing

Designing toxicology studies that comply with Good Laboratory Practice (GLP) regulations is essential for advancing a drug candidate into clinical trials under an Investigational New Drug (IND) application. GLP compliance ensures data integrity, reproducibility, and regulatory acceptance by governing bodies such as the FDA, EMA, and OECD member states.

A GLP-compliant toxicology study begins with a well-defined protocol developed under a quality management system. This protocol outlines the objectives, species and strain of test animals, dose levels, routes of administration, frequency and duration of exposure, and endpoints for toxicity assessment. Doses are typically selected based on prior non-GLP dose range-finding studies, pharmacokinetic data, and intended clinical exposure levels.

Study components must be executed under strict procedural control. This includes environmental monitoring of animal rooms, validated analytical methods for dose formulation and sample analysis, and documentation of all procedures in controlled notebooks or electronic systems. Animals are randomly assigned to treatment groups, and personnel involved in dosing, clinical observations, necropsy, and histopathology must follow SOPs to prevent bias or data contamination.

Endpoints in GLP studies typically include body weight, food consumption, clinical signs, hematology, clinical chemistry, urinalysis, organ weights, gross necropsy findings, and microscopic examination of tissues. Additional evaluations may include toxicokinetic sampling, ophthalmologic exams, neurobehavioral assessments, and reproductive organ analysis. The duration of the study—ranging from acute (e.g., 14-day) to chronic (e.g., 6-month) exposure—depends on the intended clinical use.

All data are audited by a Quality Assurance Unit (QAU) independent of the study conduct. The final report includes raw data, statistical analyses, deviations, and comprehensive interpretations, and is signed by the study director as per GLP guidelines. This package becomes part of the nonclinical section of the IND dossier submitted to regulatory authorities.

GLP-compliant toxicology testing is a critical milestone in drug development. It not only demonstrates adherence to international quality standards but also provides the reliable, traceable data necessary to make safety-based decisions about progressing to human trials.